双重膜滤过式血浆置换降低肾移植受者供体特异性抗体的临床观察  

Clinical Observation of Double Membrane Filtration Plasmapheresis in Reducing Donor Specific Antibodies in Renal Transplant Recipients

作　　者：李玉荣[1] 杨宁 LI Yu-rong;YANG Ning(Renal Transplantation Ward,Henan Province People's Hospital,Zhengzhou,450003,China)

机构地区：[1]河南省人民医院肾移植病区,郑州450003

出　　处：《黑龙江医学》2020年第2期175-176,共2页Heilongjiang Medical Journal

摘　　要：目的探究双重膜滤过式血浆置换(DFPP)降低肾移植受者供体特异性抗体(DSA)的临床效果。方法选择10例肾移植致敏受者进行DFPP治疗,时间段为2015年1月-2016年1月,对其DSA的变化情况进行严密监测,评价其治疗效果。结果肾存活率达到100.00%;平均置换血浆量与弃浆量分别为(4552±485)ml与(935±110)ml;相比治疗前,治疗后的补体、免疫球蛋白比较,差异有统计学意义(P<0.05);不良反应发生率为10.00%。结论对肾移植受者给予DFPP治疗,便于将其体内的DSA有效清除,安全性较高,可有效预防术后发生急性排斥反应,值得采纳。Objective To explore the clinical effect of double membrane filtration plasmapheresis(DFPP) on reducing donor specific antibody(DSA) in renal transplant recipients. Methods 10 cases of renal transplant sensitized recipients were treated with DFPP from Jan. 2015 to Jan. 2016. The changes of DSA were closely monitored and the therapeutic effect was evaluated. Results The renal survival rate was 100.00%, the average replacement plasma volume and the discarded plasma volume were(4552±485)ml and(935 ±110)ml respectively. The complement and immunoglobulin after treatment were significantly different(P<0.05), and the incidence of adverse reactions was 10.00%. Conclusion The treatment of renal transplant recipients with DFPP is easy to remove the DSA in the body effectively and has high safety. It can effectively prevent the acute rejection after the operation, which is worthy of adoption.

关 键 词：肾移植受者 特异性抗体 血浆置换 双重膜滤过式 

分 类 号：R692[医药卫生—泌尿科学]